• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health Establishes Halal Compliance for ClearUP, FDA-Approved, Effective, Drug-Free Alternative for Sinus Pain, Pressure, and Congestion

Jul 11, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has completed a full internal assessment of its supply chain and...

Tivic Health Establishes Halal Compliance for ClearUP, FDA-Approved, Effective, Drug-Free Alternative for Sinus Pain, Pressure, and Congestion

Jul 11, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has completed a full internal assessment of its supply chain and...

Tivic Health Announces Pricing of $1.8 Million Public Offering of Common Stock

Jul 10, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of...

Tivic Health Announces Pricing of $1.8 Million Public Offering of Common Stock

Jul 10, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of...

Tivic Health Announces Proposed Public Offering of Common Stock

Jul 7, 2023 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.